Streptococcus agalactiae surface antigens (GBS surface antigens)

Streptococcus agalactiae surface antigens, commonly referred to as Group B Streptococcus (GBS) antigens, are a diverse set of molecules located on the bacterial surface that play pivotal roles in pathogenesis and host-pathogen interactions (Source: PubMed, PMID: 30630454). These antigens include ten distinct capsular polysaccharides (CPS) and a variety of surface proteins such as the Alpha-like protein family, pili, and serine-rich repeat proteins (Source: UniProt). Functionally, these components facilitate bacterial attachment to host tissues and enable the pathogen to evade the host's innate immune response by interfering with opsonization and phagocytosis (Source: StatPearls). GBS is a major cause of neonatal morbidity and mortality, leading to conditions such as early-onset sepsis, meningitis, and pneumonia, as well as infections in pregnant women and immunocompromised adults (Source: CDC). Therapeutic interventions targeting these antigens primarily involve the development of maternal vaccines, such as hexavalent polysaccharide-protein conjugates, which aim to transfer protective antibodies to the fetus (Source: Pfizer). Additionally, monoclonal antibodies targeting specific surface proteins are being explored as prophylactic or therapeutic agents to prevent invasive GBS disease (Source: PubMed, PMID: 31524231). The diversity of these antigens, particularly the capsular serotypes, necessitates the development of multivalent or broadly cross-reactive formulations to ensure comprehensive protection across different geographic regions (Source: WHO).

Other names

Group B Streptococcus surface antigensGBS antigensStreptococcus agalactiae capsular polysaccharidesGBS surface proteinsLancefield Group B antigens

Induction of opsonophagocytic antibodies that facilitate bacterial clearance by the host immune system through passive or active immunization.